FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1584373395> ?p ?o ?g. }

• W1584373395 endingPage "29" @default.
• W1584373395 startingPage "23" @default.
• W1584373395 abstract "In addition to physical long-lasting effects such as permanent scarring and disfigurement, acne has acute and long-term psychosocial effects that affect the individual's quality of life. As with other chronic diseases, treatment success is often compromised by poor adherence.Two main objectives of this non-interventional study were to assess the long-term effect of the fixed-dose combination adapalene 0.1%/benzoyl peroxide 2.5% (adapalene-BPO gel) on quality of life and treatment adherence.Patients with moderate to severe facial acne receiving adapalene-BPO alone or in combination with other drugs were enrolled in this non-interventional study. Data were documented at baseline and after 3 and 9 months of adapalene-BPO treatment. The secondary outcomes reported here include quality of life determined by the Cardiff Acne Disability Index (CADI), treatment adherence assessed by the ECOB (Elaboration d'un outil d'evaluation de l'observance des traitements medicamenteux) questionnaire, and patient satisfaction.In total, 5131 patients were included in the efficacy evaluation. After 9 months, mean (±SD) quality of life (CADI) improved significantly from 5.9 ± 3.0 to 2.4 ± 2.7 (P < 0.0001). Patients with more severe acne at baseline tended to achieve a greater improvement in quality of life. Long-term adherence was found to be good in 83.9% of patients. Adherence had a significant effect on efficacy and quality of life (P < 0.0001 respectively). The vast majority of patients (92.1%) reported subjective improvement at the interim analysis. Accordingly, most patients (84.8%) were satisfied or very satisfied with adapalene-BPO by the end of the observation period.The clinical improvement of the disease led to an increase in quality of life among acne patients. The treatment success may be a motivation factor for patients to stay adherent over the long-term treatment course, indicating the qualification of adapalene-BPO topical gel as an appropriate medication also in the long-term usage." @default.
• W1584373395 created "2016-06-24" @default.
• W1584373395 creator A5008443906 @default.
• W1584373395 creator A5021464930 @default.
• W1584373395 creator A5032162285 @default.
• W1584373395 creator A5036630048 @default.
• W1584373395 creator A5041162052 @default.
• W1584373395 creator A5042832623 @default.
• W1584373395 creator A5053918734 @default.
• W1584373395 creator A5056011041 @default.
• W1584373395 creator A5081596079 @default.
• W1584373395 creator A5086250753 @default.
• W1584373395 date "2015-06-01" @default.
• W1584373395 modified "2023-09-26" @default.
• W1584373395 title "Effect of adapalene 0.1%/benzoyl peroxide 2.5% topical gel on quality of life and treatment adherence during long-term application in patients with predominantly moderate acne with or without concomitant medication - additional results from the non-interv" @default.
• W1584373395 cites W1493113567 @default.
• W1584373395 cites W1599184336 @default.
• W1584373395 cites W1971220253 @default.
• W1584373395 cites W1977157937 @default.
• W1584373395 cites W1985151928 @default.
• W1584373395 cites W1988387427 @default.
• W1584373395 cites W1991330761 @default.
• W1584373395 cites W2001932609 @default.
• W1584373395 cites W2006336666 @default.
• W1584373395 cites W2006745007 @default.
• W1584373395 cites W2054763414 @default.
• W1584373395 cites W2056181342 @default.
• W1584373395 cites W2058499720 @default.
• W1584373395 cites W2061436092 @default.
• W1584373395 cites W2062768474 @default.
• W1584373395 cites W2065694895 @default.
• W1584373395 cites W2085727074 @default.
• W1584373395 cites W2086529303 @default.
• W1584373395 cites W2089760394 @default.
• W1584373395 cites W2104353717 @default.
• W1584373395 cites W2116868801 @default.
• W1584373395 cites W2131592234 @default.
• W1584373395 cites W2139827667 @default.
• W1584373395 cites W81041739 @default.
• W1584373395 doi "https://doi.org/10.1111/jdv.13195" @default.
• W1584373395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26059731" @default.
• W1584373395 hasPublicationYear "2015" @default.
• W1584373395 type Work @default.
• W1584373395 sameAs 1584373395 @default.
• W1584373395 citedByCount "11" @default.
• W1584373395 countsByYear W15843733952016 @default.
• W1584373395 countsByYear W15843733952017 @default.
• W1584373395 countsByYear W15843733952018 @default.
• W1584373395 countsByYear W15843733952020 @default.
• W1584373395 countsByYear W15843733952021 @default.
• W1584373395 countsByYear W15843733952022 @default.
• W1584373395 crossrefType "journal-article" @default.
• W1584373395 hasAuthorship W1584373395A5008443906 @default.
• W1584373395 hasAuthorship W1584373395A5021464930 @default.
• W1584373395 hasAuthorship W1584373395A5032162285 @default.
• W1584373395 hasAuthorship W1584373395A5036630048 @default.
• W1584373395 hasAuthorship W1584373395A5041162052 @default.
• W1584373395 hasAuthorship W1584373395A5042832623 @default.
• W1584373395 hasAuthorship W1584373395A5053918734 @default.
• W1584373395 hasAuthorship W1584373395A5056011041 @default.
• W1584373395 hasAuthorship W1584373395A5081596079 @default.
• W1584373395 hasAuthorship W1584373395A5086250753 @default.
• W1584373395 hasConcept C118552586 @default.
• W1584373395 hasConcept C126322002 @default.
• W1584373395 hasConcept C141071460 @default.
• W1584373395 hasConcept C150966472 @default.
• W1584373395 hasConcept C159110408 @default.
• W1584373395 hasConcept C16005928 @default.
• W1584373395 hasConcept C178790620 @default.
• W1584373395 hasConcept C185592680 @default.
• W1584373395 hasConcept C2775944032 @default.
• W1584373395 hasConcept C2776173921 @default.
• W1584373395 hasConcept C2777140388 @default.
• W1584373395 hasConcept C2777673923 @default.
• W1584373395 hasConcept C2778885487 @default.
• W1584373395 hasConcept C2779384505 @default.
• W1584373395 hasConcept C2779951463 @default.
• W1584373395 hasConcept C2780564577 @default.
• W1584373395 hasConcept C44228677 @default.
• W1584373395 hasConcept C521977710 @default.
• W1584373395 hasConcept C71924100 @default.
• W1584373395 hasConceptScore W1584373395C118552586 @default.
• W1584373395 hasConceptScore W1584373395C126322002 @default.
• W1584373395 hasConceptScore W1584373395C141071460 @default.
• W1584373395 hasConceptScore W1584373395C150966472 @default.
• W1584373395 hasConceptScore W1584373395C159110408 @default.
• W1584373395 hasConceptScore W1584373395C16005928 @default.
• W1584373395 hasConceptScore W1584373395C178790620 @default.
• W1584373395 hasConceptScore W1584373395C185592680 @default.
• W1584373395 hasConceptScore W1584373395C2775944032 @default.
• W1584373395 hasConceptScore W1584373395C2776173921 @default.
• W1584373395 hasConceptScore W1584373395C2777140388 @default.
• W1584373395 hasConceptScore W1584373395C2777673923 @default.
• W1584373395 hasConceptScore W1584373395C2778885487 @default.
• W1584373395 hasConceptScore W1584373395C2779384505 @default.
• W1584373395 hasConceptScore W1584373395C2779951463 @default.
• W1584373395 hasConceptScore W1584373395C2780564577 @default.
• W1584373395 hasConceptScore W1584373395C44228677 @default.

• next